FTC: drugmakers’ agreement was cover for illegal scheme
Credit: Wikimedia Commons user LadyofProcrastination (CC BY-SA 2.0)
The Federal Trade Commission has argued that a 2010 agreement between Impax and Endo to develop a Parkinson’s treatment drug was a pretence for the first $10 million instalment Endo paid to keep a generic rival off the market.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10